Briefs: Hikal and Sun Pharma

Sun Pharma gets 8 observations from USFDA for Halol facility

USFDA conducts GCP inspection at Syngene's facility at Semicon Park, Bengaluru

The inspection concluded successfully, with the facility found to be in compliance with the required regulations

Novo Nordisk to advance subcutaneous and oral amycretin for weight management into phase 3 clinical development

The decision to advance subcutaneous and oral amycretin into phase 3 is based on feedback received from regulatory authorities

Bristol Myers Squibb announces positive results from Phase 3 Poetyk PsA-1 and PsA-2 trials of deucravacitinib in psoriatic arthritis

Mezzion secures $20 million funding to advance Phase 3 clinical development of Udenafil for fontan patients

Sigachi Industries gets ToR approval for API and specialty chemicals manufacturing facility in Andhra Pradesh

The project will be instrumental in enhancing the company's API manufacturing capacity and global reach

Aayush Wellness to form subsidiary in Singapore to drive Southeast Asia expansion

This strategic expansion marks a significant step in the company's global growth strategy

Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites

This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021

AstraZeneca’s fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia

AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations

NPPA fixes retail prices for 41 drug combinations

The NPPA has capped prices for 41 drug combinations including diabetes, cholesterol, and sleep disorder treatments